
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
pharmafile | June 3, 2025 | News story | Research and Development |Â Â American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancerÂ
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, the opportunity for cure. Yet currently only ~2 out of 10 people in the US and ~3 out of 10 people in Europe with advanced blood cancers get access to CAR T.
To address barriers to access, an international coalition is launching CAR T Vision and a new roadmap report at the American Society of Clinical Oncology (ASCO) to unite stakeholders with an urgent call-to-action to enhance patient access – with a goal to double the proportion of eligible patients treated with CAR T-cell therapy by 2030.
The Steering Committee includes leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, and health technology assessment, policy and other subject matter experts.
The CAR T Vision has been endorsed by leading organizations including the International Myeloma Foundation and Leukemia & Lymphoma Society. The report and initial activities of the CAR T Vision Steering Committee have been funded by Gilead Sciences and Kite, as the inaugural supporter of CAR T Vision.
Related Content

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …

Bristol Myers Squibb to present positive new data on lymphoma treatment
Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study …






